SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00222677

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Aspirin After Six Months or One Year of Oral Anticoagulants for the Prevention of Recurrent Venous Thromboembolism in Patients With Idiopathic Venous Thromboembolism. The WARFASA Study.

To determine whether aspirin is more effective than placebo for the prevention of recurrent symptomatic venous thromboembolism when given for at least two years after the initial 6-12 month of oral anticoagulant therapy in patients with idiopathic venous thromboembolism

NCT00222677 Venous Thromboembolism Deep Venous Thrombosis Pulmonary Embolism Atherosclerosis
MeSH: Pulmonary Embolism Thrombosis Atherosclerosis Thromboembolism Embolism Venous Thromboembolism Venous Thrombosis
HPO: Atherosclerosis Deep venous thrombosis Pulmonary embolism Thromboembolism Type IV atherosclerotic lesion Venous thrombosis

1 Interventions

Name: aspirin

Description: 100 mg daily

Type: Drug


Primary Outcomes

Measure: recurrence of VTE and/or VTE related death

Time: at least 24 months per patient

Secondary Outcomes

Measure: recurrent VTE+ death; cardiovascular events, bleeding events, critical ischemia of the lower limbs, mesenteric infarction, all cause mortality and newly diagnosed cancer

Time: at least 24 months per patient

Purpose: Treatment

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 G21210A

Exclusion Criteria: - permanent risk factors for venous thromboembolism: patients known to have antiphospholipid antibodies or lupus anticoagulant (based on local laboratory criteria) or to have homozygous factor V Leiden or homozygous prothrombin G21210A or heterozygous factor V Leiden plus heterozygous prothrombin G21210A or antithrombin III deficiency; patients with active malignancy - temporary risk factors for venous thromboembolism - any recurrence of venous thromboembolism or bleeding episode during the established 6-month period of oral anticoagulant treatment - allergy or intolerance of aspirin - clear indication for aspirin or other anti-platelet therapy (e.g. --- G21210A ---

Exclusion Criteria: - permanent risk factors for venous thromboembolism: patients known to have antiphospholipid antibodies or lupus anticoagulant (based on local laboratory criteria) or to have homozygous factor V Leiden or homozygous prothrombin G21210A or heterozygous factor V Leiden plus heterozygous prothrombin G21210A or antithrombin III deficiency; patients with active malignancy - temporary risk factors for venous thromboembolism - any recurrence of venous thromboembolism or bleeding episode during the established 6-month period of oral anticoagulant treatment - allergy or intolerance of aspirin - clear indication for aspirin or other anti-platelet therapy (e.g. --- G21210A --- --- G21210A ---



HPO Nodes


HPO:
Atherosclerosis
Genes 88
SMPD1 LDLRAP1 LDLR ACTA2 CYP7A1 ANTXR1 GLB1 FBN1 APOE APOB MAT2A ABCG8 ZNF687 LMNA AGPAT2 NPC1 LMNA GGCX FOS GGCX AGXT LMNA FOXE3 CAVIN1 SERPIND1 SMAD4 TGFBR2 SMPD1 APOB SMAD3 MYH11 CAV1 LMNA ACTA2 ABCG8 TNXB CYP27A1 COL3A1 ZMPSTE24 TGFB3 PRKG1 MYLK CEP19 LMNA ALMS1 LDLRAP1 CSF2RA APOA5 NOTCH3 ESR1 LCAT ABCA1 KCNJ5 MYH11 CSF2RB ENG TGFBR3 TGFB2 SC5D ABCC6 WRN ENPP1 HGD ANGPTL6 ELN XYLT2 LMNA ABCA1 BSCL2 LIPC PPARG SMPD1 LMNA LCAT MFAP5 ABCA1 BANF1 LMNA LOX MYH11 ABCC6 PPARG LOX XYLT1 PCSK9 NPC2 TGFBR1 ABCG5
Deep venous thrombosis
Genes 17
PROC HABP2 F5 SERPINC1 PMM2 F2 AKT1 SERPIND1 SERPINC1 PIEZO1 PROS1 MTHFR PROC THBD F13A1 PLAT F9
Pulmonary embolism
Genes 57
GDF2 MPL TLR4 COX1 SERPINC1 AKT1 STAT4 CCR1 PROS1 CBS TRNF TET2 TRNH GNAQ ND1 ACVRL1 ND4 SERPINC1 GNAQ F2 TRNW COX3 PROS1 ERAP1 AGGF1 TRNL1 PROC F13A1 KLRC4 IL10 PROS1 UBAC2 HLA-B PIGA PROC COX2 HABP2 TRNQ CD55 C4A SMAD4 IL12A-AS1 IL12A TRNS2 IL23R KCNJ5 ND6 MEFV TRNS1 PTEN ND5 MTHFR PROC FAS PLP1 ENG JAK2
Thromboembolism
Genes 17
HABP2 ADA2 F2 CBS FCGR2C SERPINC1 INHBA MTHFR PRKAR1A HRG KCNQ1 MMACHC JAK2 F13A1 EPOR PRDX1 PIGA
Type IV atherosclerotic lesion
Genes 1
APOE
Venous thrombosis
Genes 96
HLA-DPA1 FGA GDF2 MPL TLR4 PTPN22 MET SPINK1 FGG SERPINC1 AKT1 STAT4 CCR1 PROS1 TP53 SAA1 CBS TET2 GNAQ IDH1 FGB JAK2 ACVRL1 IDH2 F5 SERPINC1 CPA1 GNAQ F2 AKT1 SERPIND1 PDGFRA CTRC NOTCH1 JAK2 HBB PROS1 PIEZO1 ERAP1 AGGF1 CDH23 PROC HLA-DPB1 THBD KIF11 F13A1 KLRC4 TET2 IL10 PROS1 UBAC2 PIGM HLA-B IDH2 PROC HABP2 MPL MPL CD55 C4A SMAD4 IL12A-AS1 THPO CALR IL12A CALR IL23R JAK2 HBB CTNNB1 PLAT F9 PRSS1 MEFV TET2 PMM2 IDH1 PTEN CTLA4 PTH1R CASR SH2B3 USP8 MTHFR PROC PRTN3 MPL FAS EPOR CFTR PRKAR1A PDE4D PRSS2 ENG JAK2 PGM1